Welcome to our dedicated page for Centogene N.V. news (Ticker: CNTGF), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. stock.
The CENTOGENE (CNTGF) news page on Stock Titan provides an organized view of company announcements and disclosures related to its historical role in diagnostics and research, as well as its corporate restructuring and liquidation. Centogene N.V. has described itself as an essential life science partner for data-driven answers in rare and neurodegenerative diseases, and its news has reflected both scientific developments and major corporate decisions.
Investors and researchers can use this news feed to review updates on CENTOGENE’s multiomic activities, such as data from the Rostock International Parkinson's Disease (ROPAD) Study. Company releases have highlighted findings on genetic risk factors for Parkinson’s disease, including the RAB32 c.213C>G variant, and have described how large-scale genetic cohorts and the CENTOGENE Biodatabank support disease understanding and potential treatment development.
The news record also documents significant corporate events. In late 2024 and early 2025, CENTOGENE announced a strategic transaction to sell its operating subsidiaries, including Centogene GmbH, to an affiliate of Charme Capital Partners Limited. Subsequent releases reported shareholder approval at an Extraordinary General Meeting and the closing of the transaction, along with the company’s stated intention to liquidate its remaining subsidiaries and enter dissolution and liquidation under Dutch law.
Because Centogene N.V. has communicated that it will no longer have operations and expects its securities to cease being quoted on the OTC market, this page functions as a historical archive of CNTGF-related news. Users interested in the company’s past scientific work, pharma collaborations, and corporate restructuring can review the sequence of announcements to understand how CENTOGENE’s diagnostics and research activities evolved and were ultimately transferred to a new owner.
Centogene N.V. (OTC: CNTGF) has completed the sale of its operating subsidiaries to Charme Capital Partners affiliate, as previously announced on November 13, 2024. The transaction includes the sale of 100% ownership in Centogene GmbH and certain intercompany receivables, along with the assumption of the Company's Oxford Finance loan.
Following shareholder approval at the December 4, 2024 Extraordinary General Meeting, Centogene N.V. and its remaining subsidiary, Centogene Switzerland AG, will cease operations. The company will proceed with the liquidation of Centogene Switzerland AG and enter dissolution in accordance with Dutch law. A liquidation distribution to shareholders is expected, with the exact amount dependent on running costs and necessary reserves for expenses and liabilities.
The Company's securities will no longer be quoted on the OTC market, and its reporting obligations under the U.S. Securities Exchange Act have been suspended.
CENTOGENE (OTC: CNTGF) announced the results of its Extraordinary General Meeting, where shareholders approved all proposed resolutions. The key highlight was the approval of the previously announced sale and transfer of Centogene GmbH to Charme Capital Partners , a pan-European private equity firm. The meeting had a representation of 57.16% of the Company's issued share capital.
CENTOGENE has announced a strategic sale of its operating subsidiaries to Charme Capital Partners for EUR 8.7 million. The transaction, expected to close in Q1 2025, includes a premium of up to 25% over the company's closing price. The deal involves funding from Saudi Arabian joint venture Lifera Omics and relief from Oxford Finance liabilities. Following the transaction, CENTOGENE N.V. plans to liquidate remaining subsidiaries, with shareholders expected to receive up to $0.20 per share in liquidation distribution. The company has secured approximately 57% shareholder support for the transaction, which requires majority approval at an upcoming Extraordinary General Meeting in December 2024.
CENTOGENE has published data from its Rostock International Parkinson's Disease (ROPAD) Study in The Lancet Neurology, supporting the association of a RAB32 gene mutation with Parkinson's disease (PD). The study analyzed Whole Genome Sequencing data from 3,354 PD patients, revealing that nine patients (0.3% of the cohort) carried the RAB32 c.213C>G mutation. This prevalence is significantly higher than the 0.002% found in general population databases.
Key findings include:
- The mutation's causal role in Parkinson's disease is supported
- Age at onset did not differ between mutation-positives and negatives
- Gender proportions and certain clinical characteristics differed
- The RAB32 Ser71Arg-associated haplotype supports a single founder mutational event
CENTOGENE has launched a ROPAD Consortium to continue driving PD research and treatment through collaborative efforts, aiming to streamline access to critical data and improve the potential for advancing treatment options.